



C4X Discovery

A new dimension in drug discovery

C4X Discovery enters collaboration with Takeda Cambridge Limited

Manchester and London, UK, 26 August, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, announced today that it has signed a research collaboration agreement with Takeda Cambridge Limited (“TCB”), a UK subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. Under the agreement, C4XD’s proprietary NMR-based technology will be applied across a number of TCB’s therapeutic projects to enhance lead discovery and hit identification.

C4XD has the only technology in the world that can generate accurate, experimentally-derived 3D structures of drug molecules in just a matter of days. It can be used in conjunction with existing technologies for structure-based design such as X-ray co-crystallography. Equally, it can also be used when crystallography is unavailable, as is the case for certain GPCRs and ion channels.

Piers Morgan, CEO of C4X, said “We are delighted to partner with TCB, a leading pharma company with world class target identification and validation capabilities. This collaboration will provide increased visibility of the potential advantages and benefits of C4XD’s technology.”

Dr Andy Ayscough, Senior Director of Chemistry at TCB, commented: "We are pleased to partner with C4XD and are excited about the potential of this collaboration. C4XD has a highly innovative platform technology which complements our strong research base to accelerate product development."

--ENDS--

For further information please contact:

C4X Discovery Ltd

Piers Morgan, CEO

07912 293832

Ben Atwell / John Dineen, FTI

020 3727 1136

comms@c4xdiscovery.com

About C4X Discovery Ltd

C4X Discovery is a Manchester-based company focused on optimising drug discovery and design. It was founded in 2008 as a spin-out from the University of Manchester. The company uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. Since C4X Discovery's NMR technology shows what shapes active molecules prefer to adopt, it provides high-quality templates for drug discovery and design, and valuable information for drug candidate optimisation. In addition, the data is generated faster and more reliably than standard techniques such as X-ray co-crystallography or molecular modelling. C4X Discovery is using its technology in collaboration with the pharmaceutical industry and to build its own proprietary pipeline of high-value therapeutic candidates. It has been funded since inception by life science investor Aquarius Equity Partners.

www.c4xdiscovery.com